Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
875.95B
Market cap875.95B
Price-Earnings ratio
40.39
Price-Earnings ratio40.39
Dividend yield
0.67%
Dividend yield0.67%
Average volume
2.55M
Average volume2.55M
High today
$929.59
High today$929.59
Low today
$910.38
Low today$910.38
Open price
$918.49
Open price$918.49
Volume
3.27M
Volume3.27M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 875.95B, Eli Lilly(LLY) trades at $925.92. The stock has a price-to-earnings ratio of 40.39 and currently yields dividends of 67.2%.

During the trading session on 2026-04-18, Eli Lilly(LLY) shares reached a daily high of $929.59 and a low of $910.38. At a current price of $925.92, the stock is +1.7% higher than the low and still -0.4% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 3.27M, versus its average volume of 2.55M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

Simply Wall St 5h
Eli Lilly’s Valuation After Foundayo’s Positive ACHIEVE-4 Results And Recent Share Price Pullback

Eli Lilly (LLY) is back in focus after reporting positive Phase 3 ACHIEVE-4 results for its oral GLP-1 drug Foundayo, easing recent safety concerns and supporti...

Eli Lilly’s Valuation After Foundayo’s Positive ACHIEVE-4 Results And Recent Share Price Pullback
Nasdaq 5h
This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Key Points Eli Lilly's GLP-1 drugs are growing fast, but competition in the new drug niche is heating up. Although the stock has performed very well over the...

This Drug Stock Has Crushed the S&P 500 Over the Last Decade
TipRanks 10h
Lilly’s New Autoimmune Candidate LY4298445 Moves Through Early Testing

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper...

Analyst ratings

83%

of 35 ratings
Buy
82.9%
Hold
14.3%
Sell
2.9%

More LLY News

TipRanks 10h
Eli Lilly’s Oral Orforglipron Study Completion Signals Next Step in Diabetes and Obesity Market Race

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper...

Nasdaq 1d
Better Long-Term Buy: Eli Lilly or Viking Therapeutics?

Key Points Eli Lilly has been a growth beast, coming off an impressive year in which its revenue rose by 45%. Viking Therapeutics has an exciting GLP-1 drug i...

Better Long-Term Buy: Eli Lilly or Viking Therapeutics?
Nasdaq 1d
Is This the Biggest Game-Changer in Lilly's 150-Year History?

Key Points Eli Lilly could expand the weight loss market with its latest launch. The company should remain the leader in this niche. There are plenty of reas...

Is This the Biggest Game-Changer in Lilly's 150-Year History?
Investor's Business Daily 2d
Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied.

Technology Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. Licensing Eli Lilly's (LLY) oral weight-loss drug, Foundayo, nabbed 1,390 pres...

Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied.
MarketWatch 2d
Lilly’s new GLP-1 pill is off to a ‘robust’ start

The early success of Eli Lilly’s new GLP-1 pill is the latest signal that Americans are still eager for pills that can help them lose weight. Foundayo was appr...

Lilly’s new GLP-1 pill is off to a ‘robust’ start
The Wall Street Journal 3d
Eli Lilly Just Got Some Good News on Its Weight-Loss Pill

Eli Lilly just released results of a clinical trial that may ease concerns about the safety of its new weight-loss pill Foundayo, which seeks to rival a similar...

Eli Lilly Just Got Some Good News on Its Weight-Loss Pill
TipRanks 3d
Analysts Applaud as Eli Lilly’s Obesity Pill Is Found to Help Prevent Heart Attacks

The good news continues for pharmaceutical giant Eli Lilly (LLY) as its newly approved obesity pill has been found to help lower the risks of heart attacks. Cla...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.